Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

1.610 -0.320 (-16.58%)
Delayed Quote Updated: 4:00 PM EST, Nov 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Altimmune (ALT) Q3 2026 Earnings Call Transcript ↗
Spending is rising fast as the pemvidutide Phase 3 programs move forward. 
Via The Motley Fool
Topics Earnings
News headline image
What Altimmune (ALT) Said on Its Q3 Earnings Call ↗
Altimmune (NASDAQ:ALT) is ramping up a late-stage trial of its experimental drug pemvidutide for a serious liver disease and preparing for a December meeting with the U.S. Food and Drug Administration... 
Via MarketBeat
Topics Earnings
News headline image
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market
New HHS Direction Creates Potential Opportunities for Peptide Manufacturers, Biotech Companies, and Healthcare Innovators 
From FN Media
Via GlobeNewswire
Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NASDAQ:MBX),(NASDAQ:KLRA),(NASDAQ:ALT),(NYSE:HIMS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise ↗
Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic... 
Via MarketBeat
News headline image
Altimmune Q2 Earnings Call Highlights ↗
Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗
Altimmune (NASDAQ:ALT) reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying... 
Via MarketBeat
News headline image
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗
Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug... 
Via MarketBeat
News headline image
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated... 
Via MarketBeat
News headline image
Altimmune (ALT) Q1 2026 Earnings Transcript ↗
Altimmune (ALT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Altimmune Q1 Earnings Call Highlights ↗
Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, in the... 
Via MarketBeat
Topics Earnings
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
Via Investor Brand Network
News headline image
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
From BioMedWire
Via GlobeNewswire
What's going on in today's pre-market session ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial. 
Via Stocktwits
News headline image
Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗
Altimmune (ALT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
The maker of Wegovy hasn't said its last words just yet. 
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗
Retail sentiment on major ETFs such as SPY and QQQ turned ‘extremely bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗
Altimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits for SPY and QQQ remained ‘bearish’. 
Via Stocktwits
Topics ETFs Government Lawsuit
News headline image
ALT Stock Rallies 4% — What Does Retail Think? ↗
Earlier this month, Altimmune said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide for the treatment of patients with metabolic... 
Via Stocktwits
News headline image
Why Are Investors Looking At Altimmune Stock? ↗
Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide. 
Via Benzinga
News headline image
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗
The FDA decision was based on 24-week data from the IMPACT Phase 2b trial, showing considerable MASH resolution without worsening fibrosis. 
Via Stocktwits
News headline image
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗
New 48-week data showed its dual-action drug outperformed placebo across key non-invasive liver tests. 
Via Stocktwits
News headline image
Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗
Retail traders focused on AI-driven biopsy findings and clearer dose-response exuded increased confidence in pemvidutide’s potential. 
Via Stocktwits
News headline image
Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.